Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orloff departs FDA

Executive Summary

Metabolic & Endocrine Disorders Division Director David Orloff will step down Dec. 30 after 11 years with FDA to become the medical director of contract research organization Medpace, Inc. Orloff announced his resignation Nov. 29. Division Deputy Director Mary Parks will take over as acting director Jan. 1 until a permanent successor is named. Orloff, who oversaw FDA's review of Bristol-Myers Squibb's Pargluva, is one of several top officials to resign since summer, following the departures of Commissioner Lester Crawford and Office of Women's Health Director Susan Wood...

You may also be interested in...



Division of Metabolic & Endocrine Products director

Acting Division of Metabolic & Endocrine Products Director Mary Parks will hold the permanent position as of Aug. 6. Parks, former ODE II division deputy director and team leader for lipid-lowering drugs, was promoted to director following the departure of David Orloff Jan. 1 (1The Pink Sheet" Dec. 12, 2005, In Brief)...

UCB Aims To Tailor Myasthenia Gravis Therapy Options To Patients

Belgium’s UCB Pharma is expecting progress with new candidates for myasthenia gravis, psoriasis and osteoporosis this year.

EU Industry Decries Price Cuts And Clawbacks

A detailed report published by Medicines for Europe setting out policies affecting the off-patent industry across 22 European countries demonstrates the urgent need for pricing and reimbursement and procurement reforms, the association insists.

Topics

UsernamePublicRestriction

Register

OM008605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel